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Open modelThe rising cost of healthcare, the rising cost for drug development, the patent cliff for Big pharma, shorter patent
protection, decrease reimbursement, and the recession have made it more difﬁcult for the pharmaceutical and
biotechnology industry to develop drugs. Due to the unsustainable amount of time and money in developing a
drug that will have a signiﬁcant return on investment (ROI) it has become hard to sustain a robust pipeline.
The industry is transforming its businessmodel tomeet these challenges. In essence a paradigmshift is occurring;
the old “closed” model is giving way to a new “open” business model.
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Scientiﬁc advances, such as the relatively new ﬁeld of systems
biology are revolutionizing drug development. Thanks to systems
biology, biomedical informatics systems and convergent technologies
such as the ‘omics’, our ability to understand diseases and develop
safe and effective drugs has never been better. This review will cover:
1) Development factors engineering this paradigm shift; 2) How
systems biology is accelerating drug development and approval; 3) The
deﬁnition of an open Pharma/Biotech and how it works; and 4) How
the FDA is going “open”, what does this mean for drug approvals. Al-
though the old model is broken, the key question is will the new “open”
model be successful?tedStates. Tel.:+17819351462.
. This is an open access article under2. Drug development—then and now
To understand the paradigm shift that is taking place and why, it is
useful to understand how drug development was traditionally done
and the factors that have impelled this shift that took place over the
years affecting drug development.
2.1. Drug development—then
As depicted in Fig. 1, pharmaceutical companies used to develop
small molecule drugs focusing on the chemistry of drugs where
majority of the pathways arewell known, such as the renin–angiotensin
system that regulates blood pressure and water used to control hyper-
tension. This approach made drug development predictable because a
chemical reaction would occur the same way each time.
The majority of the development was done via a “trial and error”
method where scientist started with 1,000+ compounds and through
process of elimination pared it down to about 50–100 compounds.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Factors that Affected Drug Development
Then Now
Type of drug Small molecule Large molecule
Chemistry Biology
Known pathways -
Easier Science
Unknown pathways - More 
complex science
Time 8 - 10 years 10 - 15 years
Cost Average - $800 million Average - $1.65 billion
Pipeline Internal Internal + more external
Drug Discovery 
methodology
"Trial and Error" - start 
with 1,000 compounds 
and narrow it down
More targeted pathways - need 
to understand biology better
Clinical Trials Compared to placebo Comparative Effectiveness, to 
similar or other drugs on the 
market
High failure rate in 
Phase II and III
High failure rate in Phase II and 
III
Drug Approvals FDA non-
communicative
More communicative - ongoing
Intellectual 
property
Patent protection Shorter patent protection and 
numerous drugs going off patent 
- patent cliff
Reimbursement Formulary Superiority + decreased 
reimbursement
Funding Plentiful - many 
investors in life sciences
Risk adverse investors, fewer 
investors in life sciences -
funding is tight
Obamacare Didn't exist Life science companies footing 
the tab for everyone to have 
access to healthcare and drugs
Fig. 1. Factors that affected drug development.
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Phase 2 and Phase 3, primarily because they did not have the beneﬁt
of knowing how factors such as co-morbidities, lifestyle and environ-
ment inﬂuenced individual variation in drug responses. The entire
development process would take anywhere from 8–10 years and cost
about $800 million.
Further, the development process was entirely off limits. The
Pharma/biotech industry has been long criticized for keeping its
research and clinical data closed to the outside, and notably so for
negative results or when a serious side effect results in death. Their
rationale for keeping all information conﬁdential are:
1. Intellectual property (IP) protection. If someone steals your
research there is no legal recourse until after the competitive
product is on the market to show damages from patent infringe-
ment. But a court battle could drag on for months and even years
which is detrimental particularly to a small company who may not
have the monetary resources to legally stop their competitor from
selling their product.
2. Fierce competition to be ﬁrst in the market place. Disclosure of data
can increase competition and threaten market share.
3. Patient privacy or HIPPA for clinical trials. Patient data is conﬁdential,
unless subpoenaed by a court order.
Under this closed model, many drugs that decreased morbidity and
mortality and increased patients quality of life, have been developed.
However, developing drugs for known pathways offered little room
for innovation so researchers looked to large molecules (proteins).
With the birth of the biotechnology industry development became
more complex and difﬁcult.The challenges biotechnology companies face in developing large
molecule compounds are:
1) The biology is more complex and we don't understand it well.
2) The targets are more difﬁcult, new and unproven, therefore
more risky.
3) A delivery system is needed to get largemolecules to the desired area.
4) The FDA mandated that drugs be compared to existing drugs on the
market vs. placebo.
Therefore, the development time is longer and more costly.
2.2. Drug development–now
The sequencing of the whole human genome led to the ﬁeld of sys-
tems biology. Today, some deﬁne systems biology as the “ﬁfth prism”,
where every life form is a complex system formed by interacting
genes and macromolecules that underlie most biological processes
(1). (Vidal, 2009) Systems biology promotes the understanding of
how networks in the biological system interact to produce the behavior
of that system and how proteins interact with each other inside a cell
in response to hormones or other external stimuli (2). (Trafton, 2011)
This approach has enabled development to target segments of the
population based on biological processes, rather than one size ﬁts all.
3. How systems biology is accelerating drug development and
drug approval
Systems biology investigates interactions at the macro- and
cellular levels of biological networks and the interplay between
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(Ferrell, 2009).
Mathematics and computational modeling capture the complexity
of many variables in systems biology.
If one views human diseases as perturbations of highly interlinked
cellular networks, then diseases are highly interconnected and not
independent of each other. Therefore, it can be theorized thatmolecular
defects responsible for one of the pair of diseases can spread along
the edges of cellular networks and affect the activity of related genes
or diseases and cause or affect the outcome of the other disease (4).
(Vidal et al., 2011) Most diseases can't be explained in terms of one ge-
netic deﬁcit or one molecular impairment, said Douglas Lauffenburger,
head of MIT's Department of Biological Engineering (2). We need to
understand how many molecular components are involved, how they
work in concert, and how cells and tissues are formed, either properly
or improperly.
The systems biology approach is beneﬁting drug development in six
(6) ways:
1) More precise understanding of diseases and disease processes.
2) Faster discovery of biomarkers, companion diagnostics and thera-
peutic drugs—Microarray models (DNA proteomics) can identify
subsets of phenotypes, and pharmacogenomics can explain why
certain drugs will work on certain gene expression patterns but
not others give rise to personalized medicine.
3) Improved pre-clinical trials—By combining computational modeling
and a pilot animal study, one can better predict what will happen in
mice rather than conducting animal studies to determine efﬁcacy
and safety parameters.
4) Improved efﬁcacy—Identifying biomarkers in diseases and then
developing drugs that target these biomarkers results in better
efﬁcacy and minimal side effects. In addition, computer modeling
will predict how cells react with related co-morbidities in helping
to predict efﬁcacy.
5) Smaller clinical trials and reduced drug development cost—
Personalized medicine makes a strong case for the FDA to require
fewer homogenous patients than the 1000s of patients enrolled
in standard trials of heterogeneous patients. If the number of
patients required for all trials are smaller, the trial costs will be
signiﬁcantly less and the time to recruit, conduct the trials and
submit results will be signiﬁcantly shorter.
6) Drugs available to patients sooner—Drugs are held at a higher
standard because we have better drugs (standard of care) on
the market. Using the systems biology approach, drugs have a
higher probability of being approved because efﬁcacy and safety
would not be an issue, even if the time frame for drug development
remained the same.
4. The new business model: pharma/biotech is going “open”
Despite reservations, noted above, the pharma/biotech industry is
moving towards favoring an “open access” to their anonymized clinical
trial data for researchers who request it. They now believe that sharing
information can help other researchers and themselves better under-
stand disease progression, accelerate drug development or design
more efﬁcient clinical trials for faster drug approval thus accelerating
“the time to market” for drugs (5). (Pogorelc, 2014) There is a lot
of clinical trial data locked away which could be useful to other
researchers who have the time to analyze the data, when Big pharma
may not be due to other priorities. A number of pharma companies
have formed independent companies to manage the data and address
prior obstacles to sharing clinical trial data.
Thus, a new business model has evolved. Features are:
1) Abandon the “internal” development only philosophy to include
more external developments (more early stage collaboration,
M&A and licensing).2) Incorporate system's biology in drug discovery to understand
diseases better.
3) Include other scientiﬁc expertise such as immunology, bioinformatics
and mathematics to keep up with advancement in technology.
4) Actively pursue basic research collaboration with academic and
private research institutions to understand diseases better.
5) Lobby for more open communication with FDA with respect to
guidance and support in the drug approval process.
The industry would also like to collaborate and in so doing
open up research to get more input from fellow scientists in a
“precompetitive space.” The partnership of GlaxoSmithKline (GSK),
European Bioinformatics Institute (EMBL–EBI) and The Wellcome
Trust Sanger Institute to form the Center for Therapeutic Target
Validation (CTTV) is trying to accomplish this. The goal is to mine
the combined sources of genomics, proteomics, chemistry and disease
biology data to ﬁnd new therapeutic targets (6). (Taylor, 2013) This
information will be shared publicly. Patrick Vallance, Head of R&D at
GSK believes that the more knowledge or data obtained, the more
it de-risk things (6). This is true in discovering biomarkers. However,
it is the interpretation of this information that's the innovation. Vallance
hopes more drug companies and academic institutions will participate
in CTTV.
The following companies, or Big pharma consortiums have “openned”
their clinical trial or research databases to scientists who request access:
1) Roche—clinical trial (7) (RocheMedia Release, 2013).
2) GlaxoSmithKline—clinical trial (8) (Press Release, 2013).
3) Center for Therapeutic Target Validation (CTTV)—research (6).
4) Structural Genomics Consortium (Wellcome Trust and
GSK)—European Database (6).
5) Project Data Sphere (AstraZeneca, Bayer, Celgene, Johnson& Johnson
(J&J), Pﬁzer, Sanoﬁ and Memorial Sloan Kettering Cancer
Center)—cancer research (5).
6) TransCelerate BioPharma (Eli Lilly, J&J and Merck)—clinical trial.
5. FDA is going “open”—what does this mean for drug approval?
The FDA has been criticized in the past by industry for being
non-communicative with input and guidance in clinical trials and the
low number of drugs being approved due to delays when the FDA
requests for more data on safety and efﬁcacy as patients are awaiting
for life savings drugs to be approved. The current administration is
trying to change this negative image by incorporating an “open model”
to establish rapport and work with industry by having more open
dialog between both parties to make the drugs approval process go
more smoothly.
The FDA has allowed and provided guidance for “clinical trials (to)
be designed with adaptive features (i.e., changes in design or analyses
guided by examination of the accumulated data at an interim point
in the trial) that may make the studies more efﬁcient (e.g., shorter
duration, fewer patients) and more likely to demonstrate an effect of
the drug if one exists, or more informative (e.g., providing broader
dose-response information)(9)” (FDA, 2010) This includes both well-
established low risk designs as well as methodological designs with
less experience. These “adaptive” clinical trial designs could certainly
aid in demonstrating better efﬁcacy, or reduce cost with the reduction
in trial length and patients.
Implementing an adaptive trial requires open dialog and discussions
upfront and throughout the trial such as interim analysis on how to best
proceed forward which can make the studies more efﬁcient.
For the ﬁrst time, the FDA and European Medicines Agency (EMA)
have given “open” access to their clinical trial database and sequencing
information of drug submissions to the public for anyone to use. The
goal in sharing this information is to help accelerate drug development
and navigate through the approval process more efﬁciently by seeing
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1) NIH 1000 Genome Project—the world's largest set of data on human
genetic variation in identifying biomarkers (10). (National Institute
of Health, 2012).
2) OpenFDA—3 million records that cover medication errors and side
effects, from 2004 to 2013. The program will eventually expand to
include product recalls and labeling problems (11). (Lee, 2014).
3) FDA NextGen Sequencing—next generation sequencing information
for drug approvals (12). (Taylor, 2014).
4) EU Clinical Trial Registry—clinical trials for medicines authorized in
the 27 EU Member States and Iceland, Liechtenstein and Norway
(13). (EMA, 2011).
FDA's trend towards this model of open data sharing will have a
positive impact in the long run as it will establish a collaborative
working relationship between FDA and industry in developing better
drugs and a quicker approval process.
6. Conclusion
The industry is adopting a new “open” business model because they
realize that the only way to develop drugs faster is to put our collective
minds together; researchers, clinicians, and patients. Companies have
been doing research for decades on disease such as Alzheimers, Demen-
tia and Parkinson and have not scratched the surface to understanding
why these diseases occur and how to treat it because they are so
complex. With open collaborations this promises to change. The trend
towards personalized medicine also forces the industry to adopt new
strategies for success. Companies can't develop drugs alone and they
need to pull all resources together to ﬁgure it out. Many companies
are collaborating with other companies (for example diagnostic
companies with therapeutic companies) to develop therapeutic
drugs in hopes of getting to market faster and sharing the wealth,
and expanding the market.
However, the “open” business model must be balanced against the
ability to compete and proﬁt in order to develop and maintain a robust
pipeline. The industry has partnered with others to form independent
institution to help deﬁne a “precompetitive space” where everyone
can gain information from a single source. Whether these open models
will work is too early to tell.
Asmedicine and technology advances, developmentwill increasingly
require experts from disparate domains; mathematics, bioinformatics,
computer science, thus reinforcing the need for precompetitive open
collaboration. Once the industry ﬁgures out how best to work in the
new open environment, development should be faster, more successfuland less costly. Then negative issues that have signiﬁcantly impacted
the industry; the patent cliff, shorter patent protection, generics
and biosimilar competition, rising cost of healthcare and decreased
reimbursement for drugs, would be less impactful.
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